Nautilus Biotechnology, Inc. (NAUT)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $3.21
- As of
Kresmion compiles this page from NAUT's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Nautilus Biotechnology, Inc. (NAUT): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-10-27.
See the full NAUT dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NAUT on one page. Preview it with sample data, then open it live with a free account.
Preview the NAUT dossierActive events for NAUT
- mediumEarnings above estimates
Q3-2026: Beat consensus by 16.0%, EPS $-0.12 vs $-0.1428 estimate
- high13F: funds added
4 tracked funds increased NAUT this 2026Q2, institutional consensus
- high13F: large reduction
CITADEL ADVISORS LLC cut 92% of NAUT (2026Q2)
- high13F: large reduction
CITADEL ADVISORS LLC cut 93% of NAUT (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +646% to NAUT (2026Q2)
FREE, NO ACCOUNT
Every event on NAUT, as it fires
You are seeing 5 of 13 events recorded on NAUT since 2026-06-05.
The five above landed across 3 days. The other 8 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in NAUT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 63909J108 · 2026Q2 | $3.5M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 63909J108 · 2026Q2 | $1.3M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 63909J108 · 2026Q2 | $353K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 63909J108 · 2026Q2 | $127K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NAUT
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
NAUT against its peers
NAUT's return on equity of -37.6% ranks in the 64th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | NAUT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 9.7M | n/a | 15 |
| Operating margin | n/a | -358.9% | n/a | 11 |
| Net margin | n/a | -292.1% | n/a | 11 |
| Return on equity | -37.6% | -52.7% | 64 | 20 |
Peers (21): ALT, AUTL, ASMB, ALLO, PRTA, OVID, SPRY, TECX, RGNX, INDP, CYDY, MPLT, CCCC, EPRX, AVTX, RZLT, EDIT, DMAC, ARVN, NGNE, MNPR. Left out: TRXB (no annual filing), EIKN (no annual filing), AGMB (no annual filing), SCTX (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (NAUT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow NAUT on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to NAUT for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.